MX2021000094A - Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple. - Google Patents

Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple.

Info

Publication number
MX2021000094A
MX2021000094A MX2021000094A MX2021000094A MX2021000094A MX 2021000094 A MX2021000094 A MX 2021000094A MX 2021000094 A MX2021000094 A MX 2021000094A MX 2021000094 A MX2021000094 A MX 2021000094A MX 2021000094 A MX2021000094 A MX 2021000094A
Authority
MX
Mexico
Prior art keywords
multiple sclerosis
prevention
treatment
substituted amino
pyrimidine compound
Prior art date
Application number
MX2021000094A
Other languages
English (en)
Inventor
Martin Dyroff
David Mitchell
Orestis Papasouliotis
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2021000094A publication Critical patent/MX2021000094A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona métodos, composiciones y kits médicos para tratar y prevenir la esclerosis múltiple usando 1-(4-(((6-amino-5-(4-fenoxifenil)pirimidin-4-il)amino)metil)piper idin-1-il)prop-2-en-1-ona o una sal farmacéuticamente aceptable del mismo de acuerdo con los regímenes de dosificación preferidos.
MX2021000094A 2018-07-20 2019-07-19 Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple. MX2021000094A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862700977P 2018-07-20 2018-07-20
US201862730184P 2018-09-12 2018-09-12
US201962839273P 2019-04-26 2019-04-26
PCT/IB2019/056198 WO2020016850A1 (en) 2018-07-20 2019-07-19 A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis

Publications (1)

Publication Number Publication Date
MX2021000094A true MX2021000094A (es) 2021-03-25

Family

ID=67953828

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000094A MX2021000094A (es) 2018-07-20 2019-07-19 Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple.

Country Status (14)

Country Link
US (1) US20210260060A1 (es)
EP (1) EP3823623A1 (es)
JP (1) JP2021532104A (es)
KR (1) KR20210034623A (es)
CN (1) CN112437665A (es)
AU (1) AU2019306828A1 (es)
BR (1) BR112021000893A2 (es)
CA (1) CA3106772A1 (es)
IL (1) IL280197A (es)
MX (1) MX2021000094A (es)
SG (1) SG11202100518TA (es)
TW (1) TW202019425A (es)
UA (1) UA127744C2 (es)
WO (1) WO2020016850A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240920A1 (en) 2021-05-14 2022-11-17 Loxo Oncology, Inc. Cocrystalline forms of a bruton's tyrosine kinase inhibitor
WO2023285696A1 (en) * 2021-07-15 2023-01-19 Sandoz Ag Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one
WO2023247774A1 (en) 2022-06-24 2023-12-28 Merck Patent Gmbh Treatment regimen for autoimmune diseases and inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10060388A1 (de) * 2000-12-05 2002-06-06 Merck Patent Gmbh Verwendung von Pyrazolo [4,3-d]pyrimidinen
WO2011156900A2 (en) * 2010-06-17 2011-12-22 Waratah Pharmaceuticals Inc. Compounds, compositions and methods for treatment of multiple sclerosis
CN106831732B (zh) * 2011-06-10 2019-12-24 默克专利有限公司 生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法
US9212190B2 (en) * 2012-01-10 2015-12-15 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
US10716788B2 (en) * 2015-11-17 2020-07-21 Merck Patent Gmbh Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity
US10464923B2 (en) * 2017-02-27 2019-11-05 Merck Patent Gmbh Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone

Also Published As

Publication number Publication date
SG11202100518TA (en) 2021-02-25
US20210260060A1 (en) 2021-08-26
IL280197A (en) 2021-03-01
JP2021532104A (ja) 2021-11-25
AU2019306828A1 (en) 2021-03-11
WO2020016850A1 (en) 2020-01-23
EP3823623A1 (en) 2021-05-26
BR112021000893A2 (pt) 2021-04-13
CN112437665A (zh) 2021-03-02
TW202019425A (zh) 2020-06-01
CA3106772A1 (en) 2020-01-23
UA127744C2 (uk) 2023-12-20
KR20210034623A (ko) 2021-03-30

Similar Documents

Publication Publication Date Title
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2021000094A (es) Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12020550745A1 (en) Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
MX2021007184A (es) Formas cristalinas del derivado de 4-pirimidinsulfamida aprocitentan.
MX2022001655A (es) Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
PH12017500724A1 (en) Carbazole derivatives
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
PH12017502123A1 (en) Substituted benzamides and methods of use thereof
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12017500881A1 (en) Aurora a kinase inhibitor
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
MX2018005140A (es) Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, metodos su elaboracion y metodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histaminico h4 (h4).
PH12019500326A1 (en) Combination of fxr agonists
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
NZ772236A (en) Pharmaceutical combination for use in age-related and/or degenerative diseases
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.
EA202190270A1 (ru) Способы лечения и профилактики рассеянного склероза с применением соединений замещенного аминопиримидина